Market capitalization | $10.00k |
Enterprise Value | $38.12m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.05 |
P/S ratio (TTM) P/S ratio | 0.00 |
P/B ratio (TTM) P/B ratio | 0.00 |
Revenue growth (TTM) Revenue growth | 553.09% |
Revenue (TTM) Revenue | $9.41m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast VBI Vaccines, Inc.:
1 Analyst has issued a forecast VBI Vaccines, Inc.:
Mar '24 |
+/-
%
|
||
Revenue | 9.41 9.41 |
553%
553%
|
|
Gross Profit | -4.56 -4.56 |
65%
65%
|
|
EBITDA | -45 -45 |
45%
45%
|
EBIT (Operating Income) EBIT | -48 -48 |
44%
44%
|
Net Profit | -83 -83 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.
Head office | United States |
CEO | Jeff Baxter |
Employees | 138 |
Founded | 1965 |
Website | www.vbivaccines.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.